Skip to main content
OpenTrials

Clinical trial condition

Myelodysplastic Syndromes

Explore clinical trials studying Myelodysplastic Syndromes. Study availability and eligibility vary by location and protocol.

697 public trials 122 recruiting studies
Refine in advanced search Browse all conditions

Myelodysplastic Syndromes trial results

Completed

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

NCT00274820

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myeloproliferative Disorders, +16 more
Locations
  • Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View Trial Details
Completed

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

NCT00750009

Conditions
Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +106 more
Locations
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Fox Chase Cancer Center - Philadelphia Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

NCT01241500

Conditions
Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +17 more
Locations
  • Virginia G. Piper Cancer Center Scottsdale, Arizona, United States
  • University of California San Diego Moores Cancer Center La Jolla, California, United States
  • Stanford Cancer Center Stanford, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
View all 87 locations
View Trial Details
Completed

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

NCT01928537

Conditions
Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +17 more
Locations
  • Stanford University Cancer Center Stanford, California, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • University of Chicago Medicine Chicago, Illinois, United States
  • University of Kansas Cancer Center and Medical Pavilion Westwood, Kansas, United States
View all 35 locations
View Trial Details
Completed

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

NCT02223052

Conditions
Acute Myeloid Leukemia, Adenocarcinoma, Adnexal Diseases, +106 more
Locations
  • Scottsdale Healthcare Research Institute Scottsdale, Arizona, United States
  • Mayo Clinic - Arizona Scottsdale, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • University of Iowa Iowa City, Iowa, United States
View Trial Details
Completed

A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

NCT02145026

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +1 more
Locations
  • King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine Bangkok, Thailand
  • Rajavithi Hospital; Medicine Bangkok, Thailand
  • Ramathibodi Hospital; Division of Hematology, Department of Medicine Bangkok, Thailand
  • Siriraj Hospital; Division of Hematology, Department of Medicine Bangkok, Thailand
View Trial Details
Completed

Treatment for Chronic Pain in Patients With Advanced Cancer

NCT00003687

Conditions
Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +93 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Newfoundland Cancer Treatment and Research Foundation St. John's, Newfoundland and Labrador, Canada
  • Princess Margaret Hospital Toronto, Ontario, Canada
  • McGill University Montreal, Quebec, Canada
View Trial Details

Related conditions